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To the editor 
Renal denervation (RDN) has become a standard treatment option to lower blood pressure 
(BP) in patients with resistant hypertension in many countries since 2010. There is a huge 
interest in investigating the effect of RDN on resistant hypertension and other diseases (e.g. 
diabetes and heart failure), and 118 clinical trials have been registered at ClinicalTrials.gov. 
A large number of early clinical trials demonstrate that RDN lowers blood pressure. However, 
on 9 January 2014, Medtronic reported that RDN did not lower blood pressure in the 
randomized and sham controlled Symplicity HTN-3 trial.  In this letter, we highlighted six 
major limitations of clinical trials on RDN which need to be overcome to improve our 
understanding of the true efficacy and safety of RDN. 
1. Lack of a method to verify the completeness of RDN: RDN is thought to lower blood 
pressure by decreasing renal sympathetic nerve activity. However, no method to verify the 
completeness of RND has been established in clinical trials. The Simplicity catheter requires 
to be moved and rotated ≥4 times to cover the circumference of the renal artery, and this 
makes RDN operator-dependent. Consequently, both evaluation of the efficacy of RDN and 
identification of responders to the procedure in clinical trials are problematic. Therefore, 
research on investigating methods to verify the completeness of RDN should be emphasized. 
2. Office BP measurement: Many clinical trials on RDN primarily used office BP 
measurement. This measurement can produce white coat effects. Consequently, a big 
proportion of patients undergoing RDN had white coat hypertension, which may raise ethical 
concerns. Ambulatory BP monitoring is regarded as the gold standard to diagnose true 
hypertension and to assess cardiovascular risk. Therefore, ambulatory BP should be used as 
one of the selection criteria and changes in ambulatory BP should be one of the primary end 
points.  
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3. Drug non-adherence: Drug non-adherence is a major problem among patients with 
resistant hypertension. Measuring ambulatory BP after witnessed intake of antihypertensive 
drugs is the best way to ensure drug adherence and should be adopted in future trials [1].  
4. Low follow-up rates: The follow-up rate is generally low. For example, the 12-month 
follow-up rate was 20% and 38% in the Symplicity HTN-1 study [2] and the Heidelberg 
registry report [3], respectively. Low follow-up rates may underestimate potential side effects. 
Therefore, high follow-up rates should be emphasized. 
5. Renal artery safety: Renal artery stenosis was not thoroughly monitored. Only a small 
proportion of patients underwent computerized tomographic angiography–the gold standard 
method to detect renal artery stenosis. Using this method, the EnligHTN I trial detected this 
complication in 4.3% of patients six months after RDN [4]. This suggests a necessity to use 
this diagnosis method in future. 
6. Long-term effects: Long-term effects of RDN are not emphasized by clinical trials. For 
example, the ongoing randomized Symplicity HTN-3 study [5] allows patients in the 
randomized control group to receive RDN after completion of the six-month study. Similarly, 
in the Symplicity HTN-2 study, 46 of 54 patients in the randomized control group underwent 
RDN after completion of the six-month study. To establish the long-term effectiveness and 
safety of RDN, this crossover design should be discouraged. 
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